Mifepristone is a receptor-level antiprogestin that has the effects of terminating early pregnancy, preventing implantation, inducing menstruation, and promoting cervical ripening. It competes with progesterone for receptors to antagonize progesterone, and also has a certain binding force with glucocorticoid receptors. Mifepristone can significantly increase the sensitivity of the pregnant uterus to prostaglandins. Small doses of mifepristone sequentially combined with prostaglandin drugs can achieve satisfactory results in terminating early pregnancy.

Drug to terminate early pregnancy. It softens the cervix, increases uterine tension and intrauterine pressure. When used sequentially with mifepristone, it can significantly increase or induce the frequency and amplitude of spontaneous uterine contractions in early pregnancy. It has the pharmacological activity of E-type prostaglandins, has a mild stimulating effect on gastrointestinal smooth muscle, and inhibits gastric acid secretion in large doses.

This drug is an anti-androgen inhibitor that can inhibit the effects of male sex hormones (androgens). Androgens can also be produced in small amounts by female organs and also play a certain role as progesterone and anti-gonadotropin. For men, treatment with this drug can reduce sexual desire and sexual function, and inhibit gonadal function. These changes are reversible after stopping treatment. This drug can protect androgen-dependent target organs, such as the prostate, from the effects of androgens derived from the gonads and/or adrenal cortex. For women, this drug can reduce hirsutism, androgen-dependent alopecia and increased sebaceous gland function. Ovarian function is suppressed during treatment.

Significantly inhibit ovulation and prevent fertilized eggs from implanting, and increase the consistency of cervical mucus and the resistance of sperm penetration, thus playing a quick-acting contraceptive role

This product is a fast-acting, short-acting contraceptive. Its contraceptive mechanism is to significantly inhibit ovulation and prevent the implantation of fertilized eggs, increase the viscosity of cervical mucus, and increase the resistance to sperm penetration, thereby exerting a fast-acting contraceptive effect.

Anti-progestogen drugs at the receptor level have no progestin, estrogen, androgen and anti-estrogen activity, can bind to progesterone receptors, and have an affinity for endometrial progesterone receptors that is 5 times stronger than progesterone. They may mainly affect the normal physiological changes of the endometrium during implantation, interfere with the process of fertilized egg implantation, thereby reducing the implantation rate and avoiding pregnancy.

Progestin contraceptives can reduce the secretion of cervical mucus and increase its viscosity, which is not conducive to sperm penetration; they can affect the normal development of the endometrium, which is not conducive to the implantation of the fertilized egg; they can affect the normal activity of the fertilized egg in the fallopian tube, causing the fertilized egg to enter the uterine cavity prematurely, resulting in asynchrony with the endometrium and inhibiting implantation.